Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves

Tissue Engineering

Volumn 12, Issue 8, 2006, Pages 2263-2273

  Batten, Puspa ^a   Sarathchandra, Padmini ^a   Antoniw, Joseph W ^a   Tay, Szun Szun ^a   Lowdell, Mark W ^b   Taylor, Patricia M ^a   Yacoub, Magdi H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; HEART VALVE PROSTHESES; TISSUE; TISSUE CULTURE;

ANTI-INFLAMMATORY CYTOKINES; CELL PROLIFERATIVE RESPONSES; PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS); TOLEROGENIC CYTOKINES;

CELLS;

B7 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CHEMOATTRACTANT; CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 5; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL CONTACT; CELL PROLIFERATION; CLONAL ANERGY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HEART VALVE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPERNATANT; TH1 CELL; TISSUE ENGINEERING; UPREGULATION;

CELLS, CULTURED; CLONAL ANERGY; HEART VALVES; HUMANS; ISOANTIBODIES; MESENCHYMAL STEM CELLS; TH2 CELLS; TISSUE ENGINEERING;

EID: 33750933744     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2006.12.2263     Document Type: Article

References (43)

1. Korossis, S.A. et al. Cardiac valve replacement: a bioengineering approach. Biomed. Mater. Eng. 10, 83, 2000.
2. Yacoub, M.H. et al. Will heart valve tissue engineering change the world? Nat. Clin. Pract. Cardiovasc. Med. 2, 60, 2005.
3. Jiang, Y. et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 41, 2002.
4. Bartholomew, A. et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum. Gene Ther. 12, 1527, 2001.
5. Meirelles, L.S. et al. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br. J. Haematol. 123, 702, 2003.
6. Pittenger, M.F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143, 1999.
7. Pittenger, M.F. et al. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 95, 9, 2004.
8. Tocci, A. et al. Mesenchymal stem cell: use and perspectives. Hematol. J. 4, 92, 2003.
9. Bradley, J.A. et al. Stem cell medicine encounters the immune system. Nat. Rev. Immunol. 2, 859, 2002.
10. Frank, M.H. et al. Immunomodulatory functions of mesenchymal stem cells. Lancet 363, 1411, 2004.
11. Bartholomew, A. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42, 2002.
12. Devine, S.M. et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into non-human primates. Blood 101, 2999, 2003.
13. Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439, 2004.
14. Potian, J.A. et al. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171, 3426, 2003.
15. Aggarwal, S. et al. Human mesenchymal stem cells modulate allogencic immune cell responses. Blood 105, 1815, 2004.
16. Tse, W.T. et al. Suppression of allogencic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389, 2003.
17. Beyth, S. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214, 2005.
18. Tay, S.S. et al. Effect of cognate human CD4+ T cell and endothelial cell interactions upon chemokine production. Transplantation 78, 987, 2004.
19. Batten, P. et al. Valve interstitial cells induce donor-specific T-cell anergy. J. Thorac. Cardiovasc. Surg. 122, 129, 2001.
20. Lennon, D.P. et al. Human and animal mesenchymal progenitor cells from bone marrow: identification of serum for optimal selection and proliferation. In Vitro Cell Dev. Biol. Anim. 32, 602, 1996.
21. Johnson, D.L. et al. Immunogenicity of human heart valve endothelial cells and fibroblasts. Transplant. Proc. 29, 984, 1997.
22. Taylor, P.M. et al. Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J. Heart Valve Dis. 9, 150, 2000.
23. Page, C.S. et al. Alloproliferative responses of purified CD4+ and CD8+ T cells to endothelial cells in the absence of contaminating accessory cells. Transplantation 57, 1628, 1994.
24. Hargreaves, R. et al. The primary alloresponse of human CD4+ T cells is dependent on B7 (CD80), augmented by CD58, but relatively uninfluenced by CD54 expression. Int. Immunol. 7, 1505, 1995.
25. Di Nicola, M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838, 2002.
26. Sperling, A.I. et al. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 153, 155, 1996.
27. Adams, C.L. et al. Differences in the kinetics, amplitude, and localization of ERK activation in anergy and priming revealed al the level of individual primary T cells by laser scanning cytometry. J. Immunol. 173, 1579, 2004.
28. Hoerstrup, S.P. et al. Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation 106, 1143, 2002.
29. Liechty, K.W. et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat. Med. 6, 1282, 2000.
30. Klyushnenkova, E. et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12, 47, 2005.
31. Martins, S.L. et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104, 3429, 2004.
32. Krampera, M. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722, 2003.
33. Umemura, A. et al. Donor MHC class II antigen is essential for induction of transplantation tolerance by bone marrow cells. J. Immunol. 164, 4452, 2000.
34. Djouad, F. et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837, 2003.
35. Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619, 2004.
36. Iellem, A. et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J. Exp. Med. 194, 847, 2001.
37. O'garra, A. et al. IL-10-producing and naturally occurring CD4(+) Tregs: limiting collateral damage. J. Clin. Invest. 114, 1372, 2004.
38. Le Blanc, K. et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phyto-haemagglutinin-activated lymphocytes, Scand. J. Immunol. 60, 307, 2004.
39. Fontenot, J.D. et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329, 2005.
40. Granowitz, E.V. et al. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J. Biol. Chem. 266, 14147, 1991.
41. Suzuki, K. et al. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104, 1308, 2001.
42. Drukker, M. et al. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol. 22, 136, 2004.
43. Le Blanc, K. et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31, 890, 2003.